51
|
Nagasaka T, Nyuya A, Tanioka H, Katata Y, Yokota M, Taniguchi F, Kawai T, Mori Y, Shigeyasu K, Okawaki M, Yamamura M, Umeda Y, Tsuruta A, Ueno T, Yamaguchi Y. Distinct clinico-pathological features of hypermutant colorectal cancers with POLE pathogenic mutations, Lynch syndrome and sporadic MSI analyzed over 1,000 colorectal cancer patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
52
|
Yoshizane T, Tanaka R, Minatoguchi S, Watanabe T, Otsuka M, Nagaya M, Yagasaki H, Ono K, Ueno T, Watanabe R, Warita S, Noda T, Minatoguchi S, Kawasaki M. P1771Left ventricular strain rate during early diastole and atrial contraction by real-time three-dimensional speckle tracking echocardiography with high volume rate is a novel index of diastolic function. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
53
|
Yoshizane T, Tanaka R, Minatoguchi S, Kawamura I, Sato H, Otsuka M, Nagaya M, Ueno T, Watanabe R, Warita S, Noda T, Nagata K, Takatsu H, Minatoguchi S, Kawasaki M. P866Noninvasive and comprehensive evaluation of the impact of left ventricular pressure overload on both systolic and diastolic function using speckle tracking echocardiography. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
54
|
Yoshizane T, Tanaka R, Otsuka M, Nagaya M, Minatoguchi S, Kawamura I, Yagasaki H, Ueno T, Watanabe R, Ono K, Noda T, Amano K, Watanabe S, Minatoguchi S, Kawasaki M. P5612A novel clinical method for quantification of left ventricular pressure-strain and pressure-volume loop area: a noninvasive index of myocardial work and stroke work. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
55
|
Shimizu Y, Kadone H, Kubota S, Suzuki K, Abe T, Ueno T, Hada Y, Yamazaki M. Heterotopic triggered HAL method for patients with complete quadriplegia or paraplegia due to chronic spinal cord injury. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.1140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
56
|
Matsushita A, Saotome K, Marushima A, Ueno T, Masumoto T, Kawamoto H, Nakai K, Tsurushima H, Hada Y, Kohno Y, Yamazaki M, Sankai Y, Matsumura A. The neural network change of acute stroke patients along the robot therapy. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
57
|
Kadone H, Shimizu Y, Kubota S, Paez D, Ueno T, Hada Y, Suzuki K, Yamazaki M. Clinical assessment of stand-up and sit-down motion assist by personal standing mobility QoLo in people with spinal cord injury. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.1168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
58
|
Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Ann Oncol 2018; 28:128-135. [PMID: 28177460 DOI: 10.1093/annonc/mdw434] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Background We performed whole-exome sequencing of pretreatment biopsies and examined whether genome-wide metrics of overall mutational load, clonal heterogeneity or alterations at variant, gene, and pathway levels are associated with treatment response and survival. Patients and Methods Two hundred and three biopsies from the NeoALTTO trial were analyzed. Mutations were called with MuTect, and Strelka, using pooled normal DNA. Associations between DNA alterations and outcome were evaluated by logistic and Cox-proportional hazards regression. Results There were no recurrent single gene mutations significantly associated with pathologic complete response (pCR), except PIK3CA [odds ratio (OR) = 0.42, P = 0.0185]. Mutations in 33 of 714 pathways were significantly associated with response, but different genes were affected in different individuals. PIK3CA was present in 23 of these pathways defining a ‘trastuzumab resistance-network’ of 459 genes. Cases with mutations in this network had low pCR rates to trastuzumab (2/50, 4%) compared with cases with no mutations (9/16, 56%), OR = 0.035; P < 0.001. Mutations in the ‘Regulation of RhoA activity’ pathway were associated with higher pCR rate to lapatinib (OR = 14.8, adjusted P = 0.001), lapatinib + trastuzumab (OR = 3.0, adjusted P = 0.09), and all arms combined (OR = 3.77, adjusted P = 0.02). Patients (n = 124) with mutations in the trastuzumab resistance network but intact RhoA pathway had 2% (1/41) pCR rate with trastuzumab alone (OR = 0.026, P = 0.001) but adding lapatinib increased pCR rate to 45% (17/38, OR = 1.68, P = 0.3). Patients (n = 46) who had no mutations in either gene set had 6% pCR rate (1/15) with lapatinib, but had the highest pCR rate, 52% (8/15) with trastuzumab alone. Conclusions Mutations in the RhoA pathway are associated with pCR to lapatinib and mutations in a PIK3CA-related network are associated with resistance to trastuzumab. The combined mutation status of these two pathways could define patients with very low response rate to trastuzumab alone that can be augmented by adding lapatinib or substituting trastuzumab with lapatinib.
Collapse
|
59
|
Honda M, Ito W, Ueno T, Wada M, Narisawa H, Kato N. 0632 Analysis of Sleep Bout Duration: A New Marker to Differentiate Narcolepsy Type 1. Sleep 2018. [DOI: 10.1093/sleep/zsy061.631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
60
|
Narita J, Kogaki S, Ishigaki S, Torigoe F, Ishii R, Ishida H, Ozono K, Taira M, Ueno T, Sawa Y. Prolonged but Successful Weaning from Berlin Heart EXCOR After a Long-term Mechanical Unloading in Infantile DCM. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.1058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
61
|
Saito S, Toda K, Miyagawa S, Yoshikawa Y, Hata H, Domae K, Matsuura R, Ueno T, Kuratani T, Sawa Y. New Heart Allocation System to Rescue the Patients With Severe Biventricular Failure. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
62
|
Taira M, Ueno T, Kido T, Kanaya T, Okuda N, Matsunaga Y, Toda K, Kuratani T, Sawa Y. Long Term Results of Mechanical Circulatory Support as Bridge to Transplant in Severe Heart Failure Pediatric Patients. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.1057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
63
|
Kihara Y, Konno O, Yokoyama T, Nakamura Y, Ueno T, Iwamoto H. An Examination of Pregnancy Cases After Kidney Transplantation: Single-Center Experience. Transplant Proc 2018; 50:2531-2534. [PMID: 30316392 DOI: 10.1016/j.transproceed.2018.03.081] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Accepted: 03/02/2018] [Indexed: 10/17/2022]
Abstract
INTRODUCTION The number of young women who wish to become pregnant opting for kidney transplants is increasing, as becoming pregnant under hemodialysis or peritoneal dialysis is associated with many risks. However, there have been reports indicating that these patients are subject to a higher risk of miscarriage compared to women with normal renal function. We examine and report cases of patients that experienced pregnancy after undergoing kidney transplantation at our hospital. SUBJECTS AND METHOD Of the kidney transplantation cases that were performed at our hospital between 1985 and 2016, there were 7 cases of pregnancy. The serum creatinine levels, urine protein findings, etc, of these 7 cases were examined during the pre-pregnancy, pregnancy, childbirth, and postpartum periods. RESULTS All 7 cases were able to give birth. There were two cases of transient postpartum hypertension. There were no cases of obvious pregnancy toxemia or fetal growth retardation. Two of the cases resulted in the failure of the transplanted kidneys. DISCUSSION According to previous studies on pregnancy and childbirth after kidney transplantation, the presence of high blood pressure and proteinuria as well as the renal function at the time of pregnancy is closely associated with postpartum renal function. Urine protein was detected prior to pregnancy in both cases and resulted in the failure of the transplanted kidneys. The influence of immunosuppressants on the mother and fetus is also an important consideration. CONCLUSION We believe it is extremely important to ensure a thorough informed consent process prior to pregnancy and systematic use of immunosuppressants for young female transplant recipients.
Collapse
|
64
|
Masuda N, Sato N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Abstract P3-13-06: Tailored neoadjuvant endocrine and chemo-endocrine therapy for postmenopausal patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative primary breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-13-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aims We investigated the efficacy and safety of initial neoadjuvant endocrine therapy with exemestane (EXE) alone followed by subsequent tailored treatment with EXE alone for responders or EXE plus oral metronomic cyclophosphamide (CPA) for non-responders.
Methods In this multicenter open-label phase II study, we enrolled postmenopausal patients with primary invasive estrogen receptor (ER)-positive, HER2-negative, stage I–IIIA (T1c–T3 N0–2 M0) breast cancer and Ki67 index ≤ 30%. Patients first received EXE 25mg/day for 12 weeks. Based on clinical response and change in Ki67 index in response to the initial therapy, patients who achieved complete response (CR), partial response (PR) with Ki67 index ≤5% after treatment, or stable disease (SD) with Ki67 index ≤5% both before and after treatment were defined as responders. Non-responders were defined as patients with PR and Ki67 index >5% after treatment, or SD and Ki67 index >5% before or after treatment. For the subsequent 24 weeks, responders continued the EXE monotherapy (continued EXE group), whereas non-responders switched to combination therapy with EXE plus CPA 50mg/day (EXE+CPA group). The primary endpoint was clinical response (CR and PR) at weeks 24 and 36.
Results A total of 59 patients (median age 69 years, range 53–86 years) were enrolled between January 2011 and July 2015. After exclusion of 3 (2 with progressive disease, 1 with an adverse event, AE) who discontinued treatment in the initial 12-week EXE monotherapy period, 56 remained enrolled to receive subsequent treatment. After 8–12 weeks of the initial EXE monotherapy, 14 patients were classified as responders (9 with PR and Ki67 index ≤5% after treatment; 5 with SD and Ki67 index ≤5% before and after treatment), whereas 42 were classified as non-responders (3 with PR and Ki67 index >5% after treatment; 39 with SD and Ki67 index >5% before or after treatment). Clinical response rates at weeks 24 and 36 were 85% (12/14, 95%CI 57.2–98.2%) and 76% (10/13, 95%CI 46.2–95.0%), respectively, in the continued EXE group, and 56% (23/41, 95%CI 39.7–71.5%) and 76% (30/39, 95%CI 60.7–88.9%), respectively, in the EXE+CPA group. At week 36, no significant difference was found in median Ki67 index between the continued EXE and EXE+CPA groups (3.5% and 4.0%, respectively). The proportion of patients with preoperative endocrine prognostic index (PEPI) 0 was also similar between the continued EXE and EXE+CPA groups (21.4% and 23.8%, respectively). The breast-conserving surgery rate was 71.4% and 69.0%, respectively. Grade 3 AEs were elevated liver enzymes (1 patient) in the continued EXE group, and gastritis, hypertriglyceridemia, and bone mineral density loss (1 patient each) in the EXE+CPA group.
Conclusion Switching from EXE monotherapy to EXE+CPA combination therapy based on clinical response and biological response (change in Ki67 index) to initial therapy improved subsequent clinical response in non-responders. Favorable clinical response to EXE alone was maintained in responders. Tailored neoadjuvant endocrine and chemo-endocrine therapy was shown to be effective in postmenopausal ER-positive breast cancer patients. (JBCRG-11CPA; UMIN000004751)
Citation Format: Masuda N, Sato N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Tailored neoadjuvant endocrine and chemo-endocrine therapy for postmenopausal patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative primary breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-13-06.
Collapse
|
65
|
Ueno T, Kon T, Haga R, Nishijima H, Tomiyama M. Motor vehicle accidents in Parkinson's disease: A questionnaire study. Acta Neurol Scand 2018; 137:218-223. [PMID: 28948617 DOI: 10.1111/ane.12849] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/11/2017] [Indexed: 12/01/2022]
Abstract
OBJECTIVES Few studies have investigated the risk factors for motor vehicle accidents (MVA) in individuals with Parkinson's disease (PD) in Japan. MATERIALS AND METHODS We sent an anonymous questionnaire to 1417 patients with PD who had received medical care certificates for Intractable Diseases during the 2014 fiscal year from the Aomori Prefectural Government in Japan. Data from patients with PD who previously or currently held a driving license at the time of the survey were analyzed. RESULTS Complete datasets were obtained from 384 patients with PD who were either past or present driving license holders. Fifty-seven patients had caused at least one MVA in the last 5 years before the survey. Logistic regression analyses revealed that ergot-dopamine agonist (DA) use and excessive daytime sleepiness (Epworth Sleepiness Scale score ≥ 10) were the best predictors of MVAs. Patients having caused non-sleep-related MVAs had significantly longer disease durations, more frequent ergot-DA use, and higher cognition and communication subscores on the Parkinson's Disease Questionnaire-39 than those without non-sleep-related MVAs (P < .05). The Epworth Sleepiness Scale scores of PD patients with sleep-related MVAs were significantly higher than those of patients without sleep-related MVAs (P < .01). CONCLUSIONS Excessive daytime sleepiness and ergot-DA use may be important predictive risk factors for MVAs in PD. Daytime sleepiness appears to be related to sleep-related MVAs in PD, whereas disease progression and ergot-DA use may contribute to non-sleep-related MVAs.
Collapse
|
66
|
Conway J, Miera O, Adachi I, Maeda K, Eghtesady P, Henderson HT, Guleserian K, Fan CPS, Kirk R, Canter C, Pac M, VanderPluym C, Eastaugh L, Buchholz H, Zimpfer D, Turek J, Fenton M, Neibler R, Kirklin J, Padalino M, Lorts A, Hassan M, Lytrivi I, Auerbach S, Slaughter M, Schweiger M, Ueno T, Davies R, Lamour J, Schmitto J, Zinn M, Human D, Scheel J, Li Y, Parrino P, Borik Chiger S, Stiller B, Dumfarth J, Morales D. Worldwide Experience of a Durable Centrifugal Flow Pump in Pediatric Patients. Semin Thorac Cardiovasc Surg 2018; 30:327-335. [DOI: 10.1053/j.semtcvs.2018.03.003] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/06/2018] [Indexed: 11/11/2022]
|
67
|
Nakashima Y, Niizeki N, Usuki D, Ueno T, Kumagai T. Evaluation of surface roughness of alginate impression materials. Dent Mater 2018. [DOI: 10.1016/j.dental.2018.08.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
68
|
Maki Y, Ueno T, Sugimoto R, Harada D, Uwatsu K, Kozuki T, Nishikawa A, Nogami N, Kataoka M, Yamashita M. P2.05-009 Outcome of Stereotactic Body Radiotherapy for Clinical Stage I Non Small Cell Lung Cancer and CT Findings: Comparison with Surgical Resection. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.11.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
69
|
Hasegawa T, Tomita J, Hashimoto R, Ueno T, Kume S, Kume K. Sweetness induces sleep through gustatory signalling independent of nutritional value in a starved fruit fly. Sci Rep 2017; 7:14355. [PMID: 29084998 PMCID: PMC5662574 DOI: 10.1038/s41598-017-14608-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Accepted: 10/10/2017] [Indexed: 11/09/2022] Open
Abstract
Starvation reduces sleep in various animal species including humans and fruit flies. Immediate hunger and the following insufficient nutritional status resulting from starvation may affect sleep and arousal differently. In order to clarify the mechanism underlying the relationship between diet and sleep, we analysed the sleep behaviour of Drosophila melanogaster that were either starved or fed with different types of sugars. Starved flies showed longer activity bouts, short sleep bouts and a decreased arousal threshold. Non-nutritive sweeteners such as sucralose and arabinose, which are sweet but not nutritive, induced sleep in starved flies, but sleep bout length and the arousal threshold was short and decreased, respectively. On the other hand, sorbitol, which is not sweet but nutritive, did not induce sleep, but slightly increased the lowered arousal threshold. Activation of sweetness receptor expressing neurons induced sleep in starved flies. These results suggest that sweetness alone is sufficient to induce sleep in starved flies and that the nutritional status affects sleep homeostasis by decreasing the arousal threshold, which resulted in short sleep bouts in Drosophila.
Collapse
|
70
|
Nozaki T, Rafijah G, Yang L, Ueno T, Horiuchi S, Hitt D, Yoshioka H. High-resolution 3 T MRI of traumatic and degenerative triangular fibrocartilage complex (TFCC) abnormalities using Palmer and Outerbridge classifications. Clin Radiol 2017; 72:904.e1-904.e10. [DOI: 10.1016/j.crad.2017.04.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Revised: 04/05/2017] [Accepted: 04/11/2017] [Indexed: 11/16/2022]
|
71
|
Suzuki C, Kon T, Funamizu Y, Ueno T, Haga R, Nishijima H, Arai A, Nunomura J, Tomiyama M, Baba M, Mizukami H, Yagihashi S. Loss of intraepidermal nerve fibers in Guillan-Barre syndrome. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
72
|
Tomiyama M, Ueno T, Nishijima H, Kon T, Funamizu Y, Haga R, Arai A, Suzuki C, Nunomura J, Baba M. Driving license and car accident in patients with Parkinson’s disease. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
73
|
Hayashi K, Kanemoto M, Sakai K, Endo K, Ueno T, Yamada M. Taste disturbance in hereditary transthyretin amyloidosis. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
74
|
Tanaka N, Ueno T, Takama Y, Yamanaka H, Tazuke Y, Bessho K, Okuyama H. Fibroadenoma in adolescent females after living donor liver transplantation. Pediatr Transplant 2017; 21. [PMID: 28556594 DOI: 10.1111/petr.12947] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/28/2017] [Indexed: 11/29/2022]
Abstract
Breast FA is the most common breast tumor diagnosed in young women. Female renal transplant recipients on CsA have an increased risk of developing FA. However, reports of FA after LDLT have not been described. Our objectives were to determine the incidence of FA, analyze risk factors for FA, and evaluate treatment strategies in adolescent females after LDLT. A total of 18 female patients aged 10-19 years who underwent LDLT and survived at least one year after transplantation were enrolled in our study. The incidence of FA was 11.1%. To determine pre- or post-transplant conditions that are associated with FA after transplantation, the patients were divided into two groups according to the presence or absence of FA: FA group (n=2) and non-FA group (n=16). There were no differences in mean age at LDLT, mean age at breast evaluation, and mean duration between transplantation and breast evaluation between the two groups. However, there was a difference in the immunosuppressive regimen between the two groups. The FA group was maintained on CsA, whereas the non-FA group was maintained on tacrolimus. CsA might be implicated in FA development in adolescent females after LDLT.
Collapse
|
75
|
Ichikawa D, Kashiyama M, Ueno T. Tamper-Resistant Mobile Health Using Blockchain Technology. JMIR Mhealth Uhealth 2017; 5:e111. [PMID: 28747296 PMCID: PMC5550736 DOI: 10.2196/mhealth.7938] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2017] [Revised: 06/04/2017] [Accepted: 06/20/2017] [Indexed: 11/29/2022] Open
Abstract
Background Digital health technologies, including telemedicine, mobile health (mHealth), and remote monitoring, are playing a greater role in medical practice. Safe and accurate management of medical information leads to the advancement of digital health, which in turn results in a number of beneficial effects. Furthermore, mHealth can help lower costs by facilitating the delivery of care and connecting people to their health care providers. Mobile apps help empower patients and health care providers to proactively address medical conditions through near real-time monitoring and treatment, regardless of the location of the patient or the health care provider. Additionally, mHealth data are stored in servers, and consequently, data management that prevents all forms of manipulation is crucial for both medical practice and clinical trials. Objective The aim of this study was to develop and evaluate a tamper-resistant mHealth system using blockchain technology, which enables trusted and auditable computing using a decentralized network. Methods We developed an mHealth system for cognitive behavioral therapy for insomnia using a smartphone app. The volunteer data collected with the app were stored in JavaScript Object Notation format and sent to the blockchain network. Thereafter, we evaluated the tamper resistance of the data against the inconsistencies caused by artificial faults. Results Electronic medical records collected using smartphones were successfully sent to a private Hyperledger Fabric blockchain network. We verified the data update process under conditions where all the validating peers were running normally. The mHealth data were successfully updated under network faults. We further ensured that any electronic health record registered to the blockchain network was resistant to tampering and revision. The mHealth data update was compatible with tamper resistance in the blockchain network. Conclusions Blockchain serves as a tamperproof system for mHealth. Combining mHealth with blockchain technology may provide a novel solution that enables both accessibility and data transparency without a third party such as a contract research organization.
Collapse
|